Zoetis Inc. (NYSE:ZTS) Given Consensus Rating of “Buy” by Brokerages

Zoetis Inc. (NYSE:ZTSGet Free Report) has earned an average recommendation of “Buy” from the ten analysts that are currently covering the firm, MarketBeat Ratings reports. Nine research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $221.44.

ZTS has been the subject of a number of analyst reports. BTIG Research lifted their price target on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. JPMorgan Chase & Co. upped their target price on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Argus upgraded Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Stifel Nicolaus upped their target price on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, September 18th. Finally, Piper Sandler upped their target price on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th.

Get Our Latest Stock Report on ZTS

Zoetis Stock Down 0.8 %

NYSE ZTS opened at $175.25 on Monday. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. Zoetis has a 1-year low of $144.80 and a 1-year high of $201.92. The company has a 50 day moving average of $183.83 and a 200-day moving average of $180.97. The company has a market cap of $79.07 billion, a price-to-earnings ratio of 32.94, a PEG ratio of 2.69 and a beta of 0.90.

Zoetis (NYSE:ZTSGet Free Report) last released its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The company had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same period in the previous year, the business earned $1.36 earnings per share. The firm’s quarterly revenue was up 11.6% on a year-over-year basis. On average, equities research analysts expect that Zoetis will post 5.9 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be issued a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 annualized dividend and a dividend yield of 0.99%. Zoetis’s dividend payout ratio (DPR) is presently 32.33%.

Institutional Trading of Zoetis

A number of institutional investors and hedge funds have recently bought and sold shares of ZTS. Darwin Wealth Management LLC acquired a new stake in Zoetis in the third quarter valued at $31,000. First Personal Financial Services acquired a new stake in Zoetis in the third quarter valued at $33,000. Capital Performance Advisors LLP acquired a new stake in Zoetis in the third quarter valued at $33,000. Dunhill Financial LLC increased its holdings in Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after purchasing an additional 75 shares during the period. Finally, Quarry LP increased its holdings in Zoetis by 273.2% in the second quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after purchasing an additional 153 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

About Zoetis

(Get Free Report

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Featured Articles

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.